ADACEL® POLIO
Pertussis Vaccine - Acellular and Diphtheria and Tetanus Toxoids (Adsorbed)
Combined with Inactivated Poliovirus Type 1, 2 and 3 (Vero cell)

DESCRIPTION

ADACEL® POLIO is a sterile, uniform cloudy, white suspension for injection in prefilled syringes or vials.

Each 0.5 mL dose of ADACEL® POLIO contains:

- 2.5 mcg pertussis toxoid
- 5 mcg pertussis filamentous haemagglutinin
- 5 mcg pertussis fimbriae types 2 and 3
- 3 mcg pertussis pertactin
- ≥ 2 IU (2 LfU) diphtheria toxoid
- ≥ 20 IU (5 LfU) tetanus toxoid
- 40 DagU poliovirus inactivated type 1, Vero (Mahoney)
- 8 DagU poliovirus inactivated type 2, Vero (MEF1)
- 32 DagU poliovirus inactivated type 3, Vero (Saukett)
- 1.5 mg aluminium phosphate (equivalent to 0.33 mg aluminium)
- 0.6% v/v phenoxyethanol
- ≤ 0.025 mcg polymyxin B sulphate
- ≤ 0.02 mcg neomycin
- ≤ 0.2 mcg streptomycin
- ≤ 0.005 mg formaldehyde
- ≤ 0.02 mg glutaraldehyde
- ≤ 0.01% polysorbate 80
- water for injections to 0.5 mL

* The formulated content of 5LfU per 0.5 mL of tetanus toxoid is the same as in the related product Tripacel®.

The vaccine is prepared from: adsorbed purified and formaldehyde detoxified diphtheria and tetanus toxins; adsorbed purified and glutaraldehyde detoxified pertussis toxin (pertussis toxoid or PT); adsorbed purified and formaldehyde treated filamentous haemagglutinin (FHA); adsorbed purified pertactin (PRN) and fimbriae types 2 and 3 (FIM); and poliomyelitis viruses types 1, 2 and 3 cultivated on Vero cells, purified and then inactivated by formaldehyde.

ADACEL® POLIO is a diphtheria-tetanus-acellular pertussis combination vaccine (dTpa) combined with inactivated poliovirus vaccine with a reduced content of pertussis toxoid, filamentous haemagglutinin and diphtheria toxoid compared to paediatric diphtheria-tetanus-acellular pertussis (DTPa) formulations.

ADACEL® POLIO should not be used as part of a primary course of immunisation for diphtheria, tetanus, pertussis or poliomyelitis.

The manufacture of this product includes exposure to bovine materials. No evidence exists that any case of vCJD (considered to be the human form of bovine spongiform encephalopathy) has resulted from the administration of any vaccine product.

PHARMACOLOGY

Clinical Trials
The safety and immunogenicity profile of ADACEL® POLIO in adults and adolescents was shown to be comparable to that observed with a single booster dose of an adult formulation diphtheria-tetanus (Td), aP or Td Polio adsorbed vaccines containing the same amount of tetanus and diphtheria toxoids, pertussis antigens and inactivated poliovirus types 1, 2 and 3 administered separately.

The lower response to diphtheria toxoid in adults probably reflected the inclusion of some participants with an uncertain or incomplete immunisation history.

Serological correlates for protection against pertussis have not been established. On comparison with data from the two separate pertussis efficacy trials conducted in Sweden between 1992 and 1996, where primary immunisation with Sanofi Pasteur Limited’s acellular pertussis infant DTPa formulations conferred a protective efficacy of 85% against pertussis disease, it was considered that ADACEL® POLIO had elicited protective immune responses.

Immune responses of children 4 to 6 years of age, primed with 4 doses of DTPa, one month after vaccination with ADACEL® are shown in Table 2 below.
Table 2: Immune Responses 4 Weeks After Vaccination With ADACEL® (dTpa)

<table>
<thead>
<tr>
<th>Antigen</th>
<th>Criteria</th>
<th>Children 4-6 years old* (N = 265)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>Seroprotection Rates</td>
</tr>
<tr>
<td>Diphtheria (1)</td>
<td>≥0.1 IU/mL</td>
<td>100%</td>
</tr>
<tr>
<td>Tetanus (2)</td>
<td>≥0.1 IU/mL†</td>
<td>100%</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th></th>
<th>Seroconversion Rates</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pertussis (3)</td>
<td>PT ≥5 EU/mL‡</td>
</tr>
<tr>
<td></td>
<td>FHA ≥5 EU/mL‡</td>
</tr>
<tr>
<td></td>
<td>PRN ≥5 EU/mL‡</td>
</tr>
<tr>
<td></td>
<td>FIM ≥5 EU/mL‡</td>
</tr>
</tbody>
</table>

* Primed with DTPa at 2, 4 and 6 months and with a booster at 18 months of age
† Measured by ELISA
‡ EU = ELISA units: Antibody levels of >5 EU/mL were postulated as surrogate markers for protection against pertussis

Seroprotection rates 3 years post-vaccination with ADACEL® POLIO in adults and adolescents are shown in Table 3 below.

Table 3: Seroprotection Rates 3 Years Post-Vaccination with ADACEL® POLIO in Adults and Adolescents

<table>
<thead>
<tr>
<th>Antigen</th>
<th>Criteria</th>
<th>Adults and adolescents* (N = 251)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>Seroprotection Rates</td>
</tr>
<tr>
<td>Diphtheria (1)</td>
<td>≥0.01 IU/mL</td>
<td>95.6%</td>
</tr>
<tr>
<td>Tetanus (2)</td>
<td>≥0.01 IU/mL†</td>
<td>100%</td>
</tr>
<tr>
<td>Polio 1</td>
<td>≥1:8 Dilution</td>
<td>100%</td>
</tr>
<tr>
<td>Polio 2</td>
<td>≥1:8 Dilution</td>
<td>100%</td>
</tr>
<tr>
<td>Polio 3</td>
<td>≥1:8 Dilution</td>
<td>100%</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th></th>
<th>Seroconversion Rates</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pertussis</td>
<td>PT ≥5 EU/mL‡</td>
</tr>
<tr>
<td></td>
<td>FHA ≥5 EU/mL‡</td>
</tr>
<tr>
<td></td>
<td>PRN ≥5 EU/mL‡</td>
</tr>
<tr>
<td></td>
<td>FIM ≥5 EU/mL‡</td>
</tr>
</tbody>
</table>

* From the age of 11 years onwards
† Measured by ELISA
‡ EU = ELISA units: Antibody levels of >5 EU/mL were postulated as surrogate markers for protection against pertussis

Page 3 of 10
There are currently no data available on the antibody levels to any of the antigens in ADACEL® POLIO beyond four weeks post-vaccination in children.

INDICATIONS

ADACEL® POLIO is indicated for active immunisation against diphtheria, tetanus, pertussis and poliomyelitis in adults, adolescents and children aged 4 years and older as a booster following primary immunisation.

Children 4-6 years of age should have already received four doses of DTPa and IPV or OPV.

ADACEL® POLIO is not intended for primary immunisation.

The use of ADACEL® POLIO should be determined on the basis of official recommendations.

CONTRAINDICATIONS

ADACEL® POLIO should not be administered to individuals who have previously had a hypersensitivity reaction to any vaccine containing diphtheria or tetanus toxoids, poliomyelitis viruses or pertussis (acellular or whole cell).

ADACEL® POLIO should not be administered to individuals known to be hypersensitive to any component of the vaccine (see components listed in DESCRIPTION) or residues carried over from manufacture (such as formaldehyde, glutaraldehyde, streptomycin, neomycin and polymyxin B).

ADACEL® POLIO should not be administered to subjects who experienced an encephalopathy of unknown origin within 7 days of previous immunisation with a pertussis-containing vaccine, or to subjects who have experienced other neurological complications following previous immunisation with any of the antigens in ADACEL® POLIO.

WARNINGS

If Guillain-Barré Syndrome or brachial neuritis has occurred following receipt of prior vaccine containing tetanus toxoid, the decision to give any vaccine containing tetanus toxoid should be based on careful consideration of the potential benefits and possible risks, such as whether or not the primary immunisation schedule has been completed. Vaccination is usually justified for infants whose primary immunisation schedules are incomplete (i.e., fewer than three doses have been received).

PRECAUTIONS

The use of ADACEL® POLIO as a primary series, or to complete the primary series, has not been studied. A booster response will only be elicited in individuals who have been previously primed by vaccination or by natural infection.

To minimise the risk of adverse reactions, ADACEL® POLIO should not be given to adults and adolescents who have received another vaccine containing either diphtheria or tetanus within the previous three years.

An acceptable safety profile was observed following administration of ADACEL® POLIO given as soon as 4 months after a diphtheria-containing vaccine (Meningococcal C conjugate vaccine (CRM197)) and 3 years after Diphtheria toxoid (paediatric dose), tetanus toxoid and pertussis vaccine (DTPw vaccine).
There are currently no data upon which to base a recommendation for the optimal interval for administering subsequent booster doses with ADACEL® POLIO to maintain antibody levels against pertussis.

As with all injectable vaccines, appropriate medical treatment and supervision should be readily available for immediate use in case of a rare anaphylactic reaction following the administration of the vaccine. As a precautionary measure, adrenaline injection (1:1,000) must be immediately available in case of unexpected anaphylactic or serious allergic reactions.

The vaccine must be given intramuscularly, as subcutaneous administration increased the chances of a local reaction. Do not administer by intravascular injection. A persistent nodule at the site of injection may occur with all adsorbed vaccines, particularly if administered into the superficial layers of the subcutaneous tissue.

Intramuscular injections should be given with care in patients suffering from coagulation disorders, such as thrombocytopenia, because of the risk of haemorrhage. In these situations administration of ADACEL® POLIO by deep subcutaneous injection may be considered, although there is a risk of increased local reactions.

ADACEL® POLIO should not be administered into the buttocks due to the varying amount of fatty tissue in this region, nor by the intradermal route, since these methods of administration may induce a weaker immune response.

The immunogenicity of the vaccine could be reduced by immunosuppressive treatment or immunodeficiency. It is recommended to postpone the vaccination until the end of such disease or treatment if practical. Nevertheless, vaccination of HIV-infected subjects or subjects with chronic immunodeficiency, such as AIDS, is recommended even if the antibody response might be limited.

As with any vaccine, immunisation with ADACEL® POLIO may not protect 100% of susceptible individuals.

Vaccination should be deferred in the presence of any acute illness. A minor illness with a current temperature below 38.5°C, such as a mild upper respiratory infection, is not usually a reason to defer immunisation.

**Carcinogenicity, mutagenicity, impairment of fertility**

ADACEL® POLIO has not been evaluated for carcinogenicity, mutagenicity or impairment of fertility.

**Use in pregnancy (Category B2)**

The effect of ADACEL® POLIO on the development of the embryo and foetus has not been assessed. Vaccination in pregnancy is not recommended unless there is a definite risk of acquiring pertussis. As the vaccine is detoxified, risk to the embryo or the foetus is highly improbable. The benefits versus the risks of administering ADACEL® POLIO in pregnancy should carefully be evaluated when there is a high probable risk of exposure to a household contact or during an outbreak in the community.

**Use in lactation**

The effect of administration of ADACEL® POLIO during lactation has not been assessed. As ADACEL® POLIO is detoxified, any risk to the mother or the infant is highly improbable. The benefits versus the risks of administering ADACEL® POLIO during lactation should carefully be evaluated by the health-care provider, particularly when there is a high probable risk of disease transmission through exposure to a household contact, or during an outbreak in the community. The risks of disease transmission from the infected mother to the infant who may not have been fully immunised should also be evaluated.

**Use in children**

ADACEL® POLIO should not be used for primary immunisation.
ADACEL® POLIO is indicated for use in children aged four years and over.

INTERACTIONS

A clinical study has shown that ADACEL® POLIO can be safely administered concomitantly with hepatitis B vaccine, using a separate limb for the site of injection. ADACEL® POLIO has safely been given concomitantly with measles-mumps-rubella vaccine (MMR™ II). Interaction studies have not been carried out with other vaccines, biological products or therapeutic medications. However, in accordance with commonly accepted immunisation guidelines, since ADACEL® POLIO is an inactivated product, there is no theoretical reason why it should not be administered concomitantly with other vaccines or immunoglobulins at separate sites.

In the case of immunosuppressive therapy, refer to PRECAUTIONS.

ADVERSE REACTIONS

The reactions are listed within body systems and categorised by frequency according to the following definitions:

Very common  (≥ 1/10)
Common       (<1/10 and ≥ 1/100)
Uncommon      (<1/100 and ≥ 1/1,000)

Clinical Trial Experience

Adolescents and Adults (992 subjects)

In clinical studies in which ADACEL® POLIO was administered to adolescents and adults, the most frequently reported adverse reactions occurring over all age groups during the first 24 hours after vaccination included the following:

Very common: Injection site pain, erythema and swelling, tiredness, headache, bodyache, chills, nausea, fever, arthralgia or joint swelling

Common: Diarrhoea, vomiting

There was a trend for higher rates of local and systemic reactions in adolescents than in adults. In both age groups, injection site pain was the most common adverse reaction.

Late-onset local adverse reactions (i.e. a local adverse reaction which had an onset or increase in severity 3 to 14 days post-immunisation), such as injection site pain, erythema and swelling, occurred in less than 1.2%.

Table 4 summarises adverse events (%) in ADACEL® POLIO (dTpa-IPV) recipients 0 - 24 hours post vaccination:
Table 4: Adverse Events (%) in ADACEL® POLIO (dTpa-IPV) recipients 0 - 24 hours post vaccination

<table>
<thead>
<tr>
<th>Event</th>
<th>Children*</th>
<th>Adolescents†</th>
<th>Adults ‡</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Sweden 5.5 Yr</td>
<td>TD9707</td>
<td>TD9809</td>
</tr>
<tr>
<td></td>
<td>dTpa-IPV (N = 240)</td>
<td>dTpa-IPV (N = 350)</td>
<td>dTpa-IPV (N = 144)</td>
</tr>
<tr>
<td>Local Reactions</td>
<td>%</td>
<td>%</td>
<td>%</td>
</tr>
<tr>
<td>Redness (Any)</td>
<td>-</td>
<td>13.5</td>
<td>25.0</td>
</tr>
<tr>
<td>Redness (≥2 cm)</td>
<td>3.3</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Redness (≥5 cm)</td>
<td>-</td>
<td>16.4</td>
<td>21.5</td>
</tr>
<tr>
<td>Swelling (Any)</td>
<td>-</td>
<td>11.7</td>
<td>-</td>
</tr>
<tr>
<td>Swelling (≥2 cm)</td>
<td>3.3</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Swelling (≥5 cm)</td>
<td>-</td>
<td>80.8</td>
<td>95.8</td>
</tr>
<tr>
<td>Pain</td>
<td>60.8</td>
<td>87.9</td>
<td>95.8</td>
</tr>
<tr>
<td>Systemic Reactions</td>
<td>%</td>
<td>%</td>
<td>%</td>
</tr>
<tr>
<td>Fever**</td>
<td>9.7</td>
<td>10.8</td>
<td>2.1</td>
</tr>
<tr>
<td>Headache</td>
<td>-</td>
<td>26.4</td>
<td>35.4</td>
</tr>
<tr>
<td>Chills</td>
<td>-</td>
<td>13.8</td>
<td>17.4</td>
</tr>
<tr>
<td>Body ache</td>
<td>-</td>
<td>19.8</td>
<td>41.0</td>
</tr>
<tr>
<td>Tiredness</td>
<td>11.7</td>
<td>29.9</td>
<td>40.3</td>
</tr>
<tr>
<td>Sore/Swollen Joints</td>
<td>-</td>
<td>9.2</td>
<td>18.1</td>
</tr>
<tr>
<td>Nausea</td>
<td>-</td>
<td>10.6</td>
<td>13.9</td>
</tr>
<tr>
<td>Vomiting</td>
<td>0.4</td>
<td>1.2</td>
<td>1.4</td>
</tr>
<tr>
<td>Diarrhoea</td>
<td>0.4</td>
<td>1.2</td>
<td>2.1</td>
</tr>
</tbody>
</table>

* ≥5 to < 6 years in Swedish children; these children were primed with DTPa at 3, 5 and 12 months of age.
† ≥12 to < 19 years of age in TD9707, and ≥11 to <14 years of age in TD9809
‡ ≥19 to 60 years of age
§ The rates for dTpa-IPV administered alone or concomitantly with Hepatitis B vaccine were comparable.
** includes fever ≥38.0 °C

Children 3 to 5 years old (150 subjects)

In two clinical studies (U01-Td5I-303 and U01-Td5I-402) 150 children primed at 2, 3 and 4 months of age with a DTPw vaccine (with no additional dose in the second year of life) received ADACEL® POLIO at 3 to 5 years of age. The most frequently reported adverse reactions occurring during the first 7 days included the following:

Very common: Injection site pain, erythema and swelling; fatigue, fever ≥37.5 °C, irritability

Common: Injection site bruising and dermatitis; diarrhoea, vomiting and rash

Children 5 to 6 years old (240 subjects)

In a clinical study, children were primed at 3, 5 and 12 months of age with a DTPa vaccine with no additional dose in the second year of life. These children received ADACEL® POLIO at 5 to 6 years of age. The most frequently reported adverse reactions occurring during the first 24 hours included the following:

Very common: Injection site pain and swelling; fatigue
Common: Injection site erythema and pruritus; fever ≥38°C

Uncommon: Diarrhoea, vomiting

The rates of general symptoms after the first day but within 10 days after vaccination were low; only fever (≥38°C) and fatigue were reported in >10% of subjects. Transient severe swelling of the upper arm was reported in <1% of subjects.

Children 4 to 6 years old (298 subjects)

In a clinical study, children primed with DTPa at 2, 4 and 6 months and a booster at 18 months of age received ADACEL® (dTpa) at 4 to 6 years of age. The most frequently reported adverse reaction that occurred during the first 3 days was pain at 38.3%. Erythema and swelling were also commonly reported.

Post-Marketing Experience

Based on spontaneous reporting, the following additional adverse events have been reported very rarely (<1/10,000) during the postmarketing surveillance of dTpa-IPV. Their frequencies have been estimated using number of reports and estimated number of patients. However, exact incidence cannot be precisely calculated.

Blood and lymphatic disorders:
Lymphadenopathy

General disorders and administration site conditions:
- Malaise, Pallor
  - Extensive limb swelling, which may extend from the injection site beyond one or both joints and is frequently associated with erythema and sometimes with blisters, have been reported following administration of dTpa-IPV. The majority of these reactions appeared within 48 hours of vaccination and spontaneously resolved over an average of 4 days without sequelae. The risk appears to be dependent of the number of prior doses of DTPa vaccine, with a greater risk following the 4th and 5th doses.

Immune system disorders:
- Anaphylactic reactions, such as urticaria, face oedema and dyspnoea.

Potential Adverse Events

Brachial neuritis and Guillain-Barré syndrome after administration of a tetanus toxoid containing vaccine.

**DOSAGE AND ADMINISTRATION**

The same dosage, a single 0.5 mL dose, applies to all age groups. ADACEL® POLIO may be administered from the age of four years onwards.

ADACEL® POLIO should be administered in accordance with New Zealand Immunisation Handbook 2006 recommendations (4).

The New Zealand Immunisation Handbook 2006 (4) defines the population groups for whom a booster dose with a vaccine containing an adult formulation tetanus-diphtheria-acellular pertussis (dTpa and dTpa-IPV) is recommended unless contraindicated (refer to CONTRAINDICATIONS);

ADACEL® POLIO has not been studied in subjects with tetanus-prone injuries and should not be used in these circumstances.

**Methods of administration**
The vaccine’s normal appearance is a cloudy, white suspension, which may sediment during storage. Shake the vial, or the prefilled syringe, well to distribute uniformly the suspension before administering the vaccine.

Parenteral biological products should be inspected visually for extraneous particulate matter and/or discolouration prior to administration. In the event of either being observed, discard the vaccine.

When administering a dose from a stoppered vial, do not remove either the stopper or the metal seal holding it in place. Once the vial has been opened, any of its contents not used immediately should be discarded. Aseptic technique must be used for withdrawal of the dose. Before injection, the skin over the site should be cleansed with a suitable germicide.

ADACEL® POLIO should be administered intramuscularly. The preferred site is into the deltoid muscle.

The intravascular or subcutaneous routes should not be used (for exception, see PRECAUTIONS).

After insertion of the needle, ensure that the needle has not entered a blood vessel.

ADACEL® POLIO must not be mixed in the same syringe with other vaccines or other parenterally administered drugs or co-administered in the same syringe.

Product is for single use in one patient on one occasion only. Discard any residue.

OVERDOSAGE

Not applicable

PRESENTATION

ADACEL® POLIO is supplied in a prefilled syringe or vial for single dose (0.5 mL) use (vials not currently marketed). Each syringe comes with two separate needles, 16 mm and 25 mm in length. These separate needles are supplied to enable the vaccinator to choose the appropriate needle size for the vaccinee.

STORAGE

Store at 2º to 8ºC. REFRIGERATE. DO NOT FREEZE. Do not use after expiry date.

MANUFACTURER

SANOFI PASTEUR LIMITED
Toronto, Ontario, Canada

DISTRIBUTOR/SPONSOR NEW ZEALAND

sanofi-aventis new zealand limited
Level 8, James & Wells Tower
56 Cawley St
Ellerslie
Auckland
New Zealand
Tel: 0800 727 838
MEDICINE CLASSIFICATION

Prescription Medicine

DATE OF PREPARATION

March 2008

References List